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Mesenchymal stromal cell-like populations have been derived from mouse-induced pluripotent stem cells (miPSC-MSC) with the
capability for tissue regeneration. In this study, murine iPSC underwent diﬀerentiation towards an MSC-like immunophenotype.
Stable miPSC-MSC cultures expressed the MSC-associated markers, CD73, CD105, and Sca-1, but lacked expression of the
pluripotency marker, SSEA1, and hematopoietic markers, CD34 and CD45. Functionally, miPSC-MSC exhibited the potential
for trilineage diﬀerentiation into osteoblasts, adipocytes, and chondrocytes and the capacity to suppress the proliferation of
mitogen-activated splenocytes. The eﬃcacy of miPSC-MSC was assessed in an acute inﬂammation model following systemic or
local delivery into mice with subcutaneous implants containing heat-inactivated P. gingivalis. Histological analysis revealed less
inﬂammatory cellular inﬁltrate within the sponges in mice treated with miPSC-MSC cells delivered locally rather than
systemically. Assessment of proinﬂammatory cytokines in mouse spleens found that CXCL1 transcripts and protein were
reduced in mice treated with miPSC-MSC. In a periodontitis model, mice subjected to oral inoculation with P. gingivalis
revealed less bone tissue destruction and inﬂammation within the jaws when treated with miPSC-MSC compared to PBS alone.
Our results demonstrated that miPSC-MSC derived from iPSC have the capacity to control acute and chronic inﬂammatory
responses associated with the destruction of periodontal tissue. Therefore, miPSC-MSC present a promising novel source of
stromal cells which could be used in the treatment of periodontal disease and other inﬂammatory systemic diseases such as
rheumatoid arthritis.
1. Introduction
Mesenchymal stromal cells (MSC) are currently being
evaluated for their therapeutic eﬃcacy in treating a diverse
range of diseases in allogeneic settings without immuno-
suppressive therapy, due to their immune privileged status
and immunomodulatory properties [1]. Moreover, MSC
exhibit the ability to home towards and into injured/
inﬂamed sites where they provide therapeutic support
through the secretion of anti-inﬂammatory molecules,
cytokines, and trophic factors [2, 3] and through direct
cell-cell contact to inﬂuence the activities of a range of
immune cells [2, 4]. However, issues pertaining to access
to MSC and their limited growth potential and associated
reduced potency in vitro are major factors restricting the
translation of these cells into mainstream treatment
approaches [5–7]. In an attempt to overcome issues asso-
ciated with MSC yield, growth, and potency in vitro,
numerous groups have attempted to generate MSC-like
populations derived from induced pluripotent stem cells
(iPSC-MSC) [8–11]. The pluripotent nature of the donor
cells opens up the opportunity to generate unlimited
quantities of early-passage MSC for clinical use. Impor-
tantly, assessment of the tumorigenicity of implanted
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iPSC-MSC in nonhuman primates failed to identify the
formation of any tumors [12].
Assessment of the immunomodulatory properties of
iPSC-MSC has shown that they can suppress T-cell prolifer-
ation [13–19], modulate the expression of a range of cyto-
kines, promote regulatory T-cell (Treg) expansion, and
inhibit the function of both natural killer cells [17, 20] and
dendritic cells [14]. Where direct comparisons of the immu-
nomodulatory properties of iPSC-MSC and primary MSC
have been reported, iPSC-MSC have proven to be compara-
ble to MSC both in vitro and in vivo [8, 13, 16, 17, 20–22].
The eﬃcacy of iPSC-MSC has been shown in multiple
experimental disease models including, limb ischemia [8],
experimental inﬂammatory bowel disease [15], lupus
[14], and autoimmune uveitis [14] and in an autoimmune
encephalitis model of multiple sclerosis [21]. Comparative
studies reported that iPSC-MSC outperformed BMSC in
direct comparisons of their therapeutic eﬃcacy in mouse
models of limb ischemia and autoimmune encephalitis-
induced multiple sclerosis [8, 21]. The greater therapeutic
potential of iPSC-MSC has been attributed to their supe-
rior survival and engraftment ability [8, 21]. Therefore,
iPSC-MSC are emerging as a highly promising, scalable
alternative to current MSC sources for the treatment of a
wide range of immune disorders.
Periodontitis is a chronic inﬂammatory condition of the
periodontium, which results from an inﬂammatory immune
response mounted against microbial bioﬁlms on the surface
of the teeth. Initiation of the inﬂammatory immune response
is complex involving both innate and acquired immunity.
Ultimately, this immune response contributes to the peri-
odontal tissue destruction seen in periodontitis [23]. One
study has reported on the eﬀects of tumor necrosis factor
alpha-stimulated gene-6 (TSG-6) transduced PSC-MSC in a
ligature-based model of periodontitis, providing preliminary
evidence that genetically modiﬁed iPSC-MSC could serve as
an alternative stem-cell-based approach for treating peri-
odontitis [24]. The present study aimed to assess whether
iPSC-MSC can inhibit inﬂammation and bone loss associ-
ated with acute and chronic periodontitis.
2. Methods and Materials
2.1. Animals. Approval for the use of BALB/c mice in this
study was obtained from the University of Adelaide, Animal
Ethics Committee (Project M-2012-226). The mice were
housed in the University of Adelaide PC2 Animal holding
facility. Animals were evaluated daily for a number of general
health parameters, for example, dull/ruﬄed coat, a change in
temperament, reduced food/water intake, or a reluctance to
move, and body weight was recorded. All mice were ran-
domly assigned to either the control or treatment group.
2.2. Cell Culture.Mouse iPSC (miPSC) were kindly provided
by Professor Paul Verma (Monash University—Faculty of
Engineering). The miPSC were generated from tail-tip ﬁbro-
blasts from NOD/Lt mice using the transcription factors,
Oct4, Sox2, and Klf4, in combination with the histone deace-
tylase inhibitor valproic acid as previously described [25].
Diﬀerentiation into MSC-like cells was performed as previ-
ously described in the presence of 10 ng/mL of ﬁbroblast
growth factor 2 to the MSC media [11, 26].
2.3. Flow Cytometric Analysis. Single-cell suspensions were
prepared by trypsin digestion for iPSC-MSC cells, or Cell
Dissociation Buﬀer Enzyme-Free phosphate-buﬀered saline
(Thermo Fisher Scientiﬁc, MA, USA) to dissociate the iPSC
from the mouse embryonic ﬁbroblast feeder layers. Single-
cell suspensions were resuspended in blocking buﬀer consist-
ing of Hank’s balanced salt solution (Sigma-Aldrich, MO,
USA) supplemented with 5% normal human serum (Austra-
lian Red Cross, Melbourne, Australia), 5% FCS (Thermo
Fisher Scientiﬁc, MA, USA), and 1% bovine serum albumin
((BSA) ICN Biomedical, CA, USA) and incubated on ice
for 30 minutes. Approximately, 1× 105 cells were incubated
with speciﬁc cell surface marker antibodies reactive with
mouse CD34, CD45, CD73, CD105, Sca-1, SSEA1 (BD Bio-
sciences), or isotype control antibodies (10mg/mL) on ice
for 1 hour. After washing, cells were incubated for 30min
on ice with their respective secondary detection antibodies:
goat anti-mouse IgG-PE or IgM PE (Southern Biotechnology
Associates, AL, USA). After washing, the samples were ﬁxed
and then analysed using an Epics XL-MCL ﬂow cytometer
(Beckman Coulter, CA, USA). Analysis was performed using
the FloExpress software.
2.4. Trilineage Diﬀerentiation
2.4.1. Osteogenesis. Mineralization was induced as described
previously [27]. Brieﬂy, miPSC diﬀerentiated to miPSC-
MSC-like cells were seeded in triplicate in 24-well plates with
3× 104 cells/well for imaging and also seeded in six-well
plates with 2× 105 cells/well for RNA collection. Cells were
cultured in osteoinductive media (α-MEM supplemented
with 5% FCS, 100mM L-ascorbate-2-phosphate, 1mM
sodium pyruvate, 50μg/mL streptomycin, 50U/mL penicil-
lin, 2mM L-glutamine, and dexamethasone 10−7M (Mayne
Pharma, NC, USA)) and 1.8mM inorganic phosphate
(KH2PO4; BDH VWR Chemicals, PA, USA) for 28 days.
Mineral deposition was identiﬁed using Alizarin Red staining
(Alizarin Red S; Sigma-Aldrich, MO, USA). Total RNA was
extracted from the miPSC-MSC-like cells with TRIzol
(Thermo Fisher Scientiﬁc, MA, USA), under osteoductive
conditions or normal growth medium for 4 weeks.
2.4.2. Chondrogenesis. Chondrogenic induction has been
described in detail previously [28]. Brieﬂy, 5× 105 miPSC-
MSC-like cells were centrifuged at 600g into cell pellets
then cultured in polypropylene tubes in chondrogenic
media for 28 days. For histological assessment, the cell
pellets were ﬁxed, paraﬃn embedded, sectioned, stained
with hematoxylin and eosin, and immunohistochemically
stained with anticollagen type II monoclonal antibody as pre-
viously described [28]. Replicate cell pellets were washed
then digested with collagenase I (3mg/mL; Worthington
Biochemical, NJ, USA) and dispase II (4mg/mL; Roche Diag-
nostics, Basel, Switzerland), then processed for RNA with
TRIzol. To assess the level of glycosaminoglycan (GAG) syn-
thesis, 1× 105 iPSC-MSC-like cells were seeded at per well in
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96-well plates. The level of GAG synthesis was measured by
35SO4 incorporation using a TopCount NXT Microplate
Scintillation and Luminescence counter (Perkin Elmer Life
and Analytical Sciences) over a 5-day period, normalized
to DNA content per well. Quantitation of DNA was per-
formed using the Quant-iTTM PicoGreen dsDNA Assay
Kit (Thermo Fisher, MA, USA) as per the manufacturer’s
instructions, using a Polar Star Optima microplate reader
at 540nm.
2.4.3. Adipogenesis. Adipogenic potential of miPSC-MSC-
like cells was assessed as previously described [27, 29].
The miPSC-MSC-like cells (3× 103) were seeded in 24-
well plates then cultured for 28 days in adipogenic induc-
tion medium. Lipid deposits were identiﬁed with Oil Red
O (MP Biomedicals, CA, USA). RNA was isolated from
replicate plates, using TRIzol after 28 days of adipogenic
induction or under normal growth conditions.
2.5. RNA Extraction, cDNA Synthesis, and Real-Time PCR.
Total RNA was extracted from cultures using TRIzol
(Invitrogen, Grand Island, NY, USA) according to the
manufacturer’s instructions. Generation of cDNA and
real-time analysis was performed as previously described
in triplicate [30]. Real-time PCR primers (GeneWorks,
Thebarton SA, AUS) used in this study are the following:
BMP-2 (NM_007553.3) fwd 5′-gggacccgctgtcttctagt-3′, rev
5′-tcaactcaaattcgctgaggac-3′; Opn (NM_001204201.1) fwd
5′-agcaaactcttgcaagcaa-3′, rev 5′-gattcgtcagattcatccgagt-3′;
Pparγ2 (NM_001127330.2) fwd 5′-ttttccgaagaaccatccgatt-3′,
rev 5′-atggcattgtgagacatcccc-3′; C/ebpα (NM_001287514.1)
fwd 5′-caagaacagcaacgagtaccg-3′, rev 5′-ctcactggtcaactc-
cagcca-3′; Collagen Type 2α1 (NM_001113515.2) fwd
5′-gcgaccgggagcatataact-3′, rev 5′-gccctaattttcgggcatcc-3′;
Sox9 (NM_011448.4) fwd 5′-cacaagaaagaccaccccga-3′,
rev 5′-ggaccctgagattgcccaga-3′; TNFα (NM_013693.3) fwd
5′-tgcttgttcctcagcctctt-3′, rev 5′-tgggctacaggcttgtcact-3′;
CXCL1 (NM_008176.3) fwd 5′-aaccgaagtcatagccacac-3′, rev
5-gttggatttgtcactgttcagc-3′; and β-actin (NM_007393.5) fwd
5′-ttgctgacaggatgcagaag-3′, rev 5′-aagggtgtaaaacgcagctc-3′.
2.6. Inhibition of Splenocyte Proliferation. The miPSC-MSC
were inactivated by γ-irradiation (30Gy) and plated into a
96-well ﬂat-bottom plate at a concentration of 1× 105/well
24 hours before the addition of mouse splenocytes prela-
belled with 2μM of carboxyﬂuorescein diacetate succinimi-
dyl ester ((CFSE) Invitrogen, OR, USA). Splenocytes, from
three mouse donors, were cultured in the presence or absence
of miPSC-MSC at a 1 : 1 (miPSC-MSC: splenocytes) ratio, in
αMEM, P/S, sodium pyruvate, L-glut, 10% FCS, and 1μg/ml
of concanavalin A (Con A; Sigma-Aldrich, MA, USA), an
inducer of splenocyte proliferation, for 5 days. Colcemid
(Thermo Fisher, MA, USA), a cell cycle arresting agent, was
used as a positive control at a concentration of 100ng/ml.
Splenocyte proliferation was analysed by ﬂow cytometry to
detect green ﬂuorescence (CFSE), and analysis of cell divi-
sion and proliferation index (average fold expansion) was
achieved using FCS 4 express ﬂow cytometry software
(De Novo Software, Los Angeles, CA, USA). Proliferation
index in cocultures was expressed as a percentage of
PBMC proliferation in the absence of immunomodulatory
cells. All experiments were performed in triplicate.
3. Sponge Model
3.1. Heat-Killed P. gingivalis. The heat-killed P. gingivalis
(HKPG) was prepared by incubating a suspension of
these bacteria in sterile PBS with a cell density estimated
to be greater than 1011 organisms/ml (optical density
(600 nm)> 5.0) at 60°C maintained for 10min. The
absence of any viable bacteria was conﬁrmed by culturing
a small volume (100μl) of the heat-killed suspension on a
blood agar plate under the anaerobic conditions required
for P. gingivalis growth.
3.2. HKPG-Impregnated Sponges. Sterilized polyurethane
foam pieces (3× 2× 2mm) were impregnated with HKPG
by immersing and compressing the sponges in 1ml HKPG
suspension (1011 organisms/ml) and air drying at 37°C under
UV light in sterile 12-well plates overnight, to prevent
contamination.
3.3. Sponge Implantation to Induce Inﬂammation. All the
surgeries were done using the following set protocol: mice
were anaesthetized using inhalation anaesthesia by 2% v/v
isoﬂurane with O2 ﬂow rates of 2 litres per minute. Once gen-
eral anaesthesia was induced, a small 5-6mm midline dorsal
incision was made, followed by blunt dissection to create two
subcutaneous pouches in the area of the left and right shoul-
ders into which one HKPG-impregnated sponge was
implanted on either side. The wound was closed oﬀ with sur-
gical staples, and the animals were placed on a 7-day course
of antibiotics to avoid infection and administered pain relief
as required. All animals were monitored during recovery,
and postoperative observations using clinical record sheets
were performed daily. Sponges were left in situ for 21 days
and 49 days to assess treatments in the acute and chronic
phases of the inﬂammatory reaction.
3.4. Treatment during Inﬂammatory Stage. To investigate the
eﬀect of diﬀerentiated MSC-like cells frommiPSC on inﬂam-
mation, the following group treatments were conducted at
day 7 postimplantation. Each group contained 6 mice for this
study. Groups 1 and 4 PBS controls received PBS via tail vein
injection in half the mice, while the other half received PBS
via subcutaneous injection into the sponge implant zone.
Groups 2 and 5 received tail vein injections of diﬀerentiated
MSC-like cells, and Groups 3 and 6 received subcutaneous
injections into the sponge implant zone. Implanted sponges
from groups 1, 2, and 3 were retrieved at day 21 and those
in groups 4, 5, and 6 at day 49.
3.5. Retrieval Surgery. On the days of retrieval (day 21 and
day 49), animals were anaesthetised by inhalation anaesthe-
sia, blood was collected by cardiac puncture, and then the
animals were immediately killed by CO2 inhalation and cer-
vical dislocation. The sponges were retrieved and cut in half.
One-half of the sponge was prepared for histological
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assessment and the other half for biochemical analysis of
cytokines. The spleens were also collected for biochemical
analysis and other organs for routine histology.
3.6. Histological Preparation and Analysis of Inﬂamed
Sponges. One-half of the sponge from both the left and right
ﬂank was placed into 10% phosphate buﬀered formalin at
time of retrieval, kept in formalin at room temperature for
two days, washed in PBS, and processed for paraﬃn embed-
ding. Serial paraﬃn sections (7μm) were prepared and
stained with haematoxylin and eosin. For each of the mice,
one of the sections was chosen at random and evaluated at
10x magniﬁcation using a light microscope in order to assign
a semiquantitative analysis score for both the severity and
inﬁltration of inﬂammation. The scoring of the severity of
inﬂammatory changes was based on the percentage of
chronic inﬂammatory cells (predominantly lymphocytes),
using a point scale: 0 =normal tissue 0–5% inﬂammatory
cells; 1 =mild inﬂammation 5–25% inﬂammatory cells;
2 =moderate inﬂammation 25–50% inﬂammatory cells; and
3= severe inﬂammation 50% inﬂammatory cells. Similarly,
the scoring system for inﬂammation inﬁltration into the
sponge was 1= 0–20% inﬁltration, 2 = 20–50% inﬁltration,
and 3≥ 50% inﬁltration. The scoring was performed by 2
independent observers who were blinded to the samples.
The histological slides were all coded and randomised and
then presented to the independent observers for analysis.
3.7. Post miPSC-MSC Treatment on Experimental
Periodontitis by Oral Inoculation of P. gingivalus. To further
investigate the eﬃcacy of miPSC-MSC-like cells in periodon-
titis, we performed a pilot study to assess the eﬀects of
miPSC-MSC-like cells on a bacterial-induced periodontitis
mouse model [31, 32]. Periodontitis was induced in mice
through a two-stage inoculation sequence involving the local
application of P. gingivalis to the teeth as well as the systemic
administration through oral gavage. Once periodontitis had
been established (day 44), half of the mice were treated with
an injection, via tail vein of miPSC-MSC-like cells (n = 3)
whilst the other half received an injection of PBS (n = 3).
Fourteen days after the administration of miPSC-MSC-like
cells, the experiment was completed. Mice underwent
micro-CT analysis to assess the CEJ-ABC bone volume.
The jaws of the mice were processed for histological analysis.
All animal inoculations were performed in a PC2 animal
holding facility at the SA Pathology Veterinary Facility.
3.8. Live Animal Microcomputed Tomography. Mice were
scanned using the Skyscan 1076 high resolution live ani-
mal computed tomography (micro-CT) (SkyScan, Bruker,
Belgium) as described in detail previously [31]. Measure-
ments were made of any changes in the cementoenamel
junction to the alveolar bone crest (CEJ-ABC) length in
the jaws, in the mice treated with miPSC-MSC-like cells
versus controls. The scanning width was set to 35mm
with a resolution of 9mm. Animals were anaesthetised
prior to scanning with a mixture of ketamine and xylazine
and positioned on a polystyrene foam holder then placed
within an enclosed container with a HEPA ﬁlter at both
ends. The container was placed in the 3 cm carbon ﬁbre
bed of the micro CT scanner. Mice were scanned three
times during the study; preinduction of experimental
inﬂammatory disease to obtain baseline measurements
(day 0), post experimental disease induction (day 44),
and again at the completion of the study, day 58.
3.9. Microcomputed Tomography Data Processing. Scans
were reconstructed using SkyScan NRecon software (Version
1.6.6.0). Settings used are smoothing=1, ring artefact = 15,
and beam hardening =30%, andmisalignment compensation
was adjusted manually. The BMP ﬁles created were opened in
CT Analyser (Version 1.12.0.0+) to create a volume of inter-
est. DataViewer (Version 1.5.1.2 64-bit) was used to realign
images and save the appropriate plane for the CEJ-ABC
distance. Sagittal and coronal images were to determine the
CEJ-ABC distance. The images were then opened in CT Ana-
lyser to measure CEJ-ABC distance. The histogram settings
were set at 100 and 255 to measure CEJ-ABC junction
distance. The CEJ-ABC distance was measured between the
second and third molars on three slices for each mouse [33].
3.10. Histological Scoring for Periodontitis. At day 63, mice
were euthanized by CO2 inhalation. The heads were ﬁxed
in 10% buﬀered formalin for 48 hours. Following ﬁxation,
the specimens were rinsed thoroughly in PBS and then decal-
ciﬁed in 10% EDTA, with agitation for 14 days, replacing the
solution regularly over this period. Thorough decalciﬁcation
was conﬁrmed by radiography, and specimens were paraﬃn
embedded then sectioned at a thickness of 7μm. For inﬂam-
matory scoring and histological analysis, sections were
stained with haematoxylin and eosin. Slides were observed
using a Leica DM1000 microscope and imaged with a con-
nected Leica DFC450 Camera system (Leica Microsystems,
Wetzlar, Germany). The periodontium of the maxillary
molars was assessed for inﬂammation with interdental
inﬂammatory cell inﬁltrate, change to tissue architecture,
papilla reduction, and presence of osteoclasts particularly
between the ﬁrst and second molars. The severity of each
parameter was scored on a scale from 0 to 3 (0=normal,
1 =mild eﬀect, 2 =moderate eﬀect, and 3= severe eﬀect).
The sections assessed for each mouse were all at the level
where the distal root of the ﬁrst molar and proximal root of
the second molar were clearly visible [32].
3.11. Statistical Analysis. The data collected from this study
were analysed by one-way ANOVA. When the global test
was statistically signiﬁcant (p < 0 05), post hoc comparisons
were performed using the Tukey or Bonferroni’s multiple
comparison, 95% conﬁdence level. Unpaired t-tests (two tail)
were also used for 2 group comparisons. All testing was car-
ried out with GraphPad Prism 6 as the statistical analysis
package. Signiﬁcance levels were set at p < 0 05 for all tests.
4. Results
4.1. miPSC-MSC Exhibit a MSC-Like Immunophenotype.
Under MSC inductive conditions, the miPSC underwent dif-
ferentiation towards an MSC-like immunophenotype. Flow
cytometric analysis was used to analyse miPSC and miPSC-
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MSC with respect to MSC-associated markers. Nonin-
duced miPSC were found to express the MSC-associated
markers CD73 (76.08%), CD105 (23.14%), and Sca-1
(82.64%) and the pluripotent marker SSEA1 (74.78%)
(Figure 1). Following MSC induction, miPSC-MSC dis-
played high expression levels of CD73 and Sca-1, but
lacked expression of SSEA1, CD34, and CD45. However,
CD105 was only expressed on a minor subset of miPSC-
MSC. Fluorescence-activated cell sorting was subsequently
performed to isolate stable CD105 positive expressing
miPSC-MSC from the mixed presort population of CD105-
positive and CD105-negative cells (Figure 1). Postsort
CD105-positive-selected miPSC-MSC were subsequently
used in functional experiments described below.
4.2. Trilineage Diﬀerentiation Potential of miPSC-MSC. The
ability of miPSC-MSC to undergo trilineage diﬀerentiation
into osteoblasts, adipocytes, and chondrocytes was assessed
in vitro to conﬁrm that the cells generated were MSC-like
cells. The ability of the miPSC-MSC to undergo osteogenic
diﬀerentiation was demonstrated by the presence of Alizarin
Red-positive-mineralised calcium deposits (Figure 2(a)).
Osteogenic induction of miPSC-MSC resulted in a statisti-
cally signiﬁcant increase in expression of the osteogenic-
associated genes and bone sialoprotein-2 and osteopontin
(Figure 2(a)). The adipogenic potential of the miPSC-MSC
was shown by the presence of Oil Red O-positive lipid-
containing adipocytes (Figure 2(b)). Adipogenic induction
resulted in a statistically signiﬁcant increase in expression
of the adipocyte-associated genes, CCAAT/enhancer-bind-
ing protein alpha (C/EBPα), and peroxisome proliferator-
activated receptor gamma (PPAR-γ) (Figure 2(b)). Finally,
the chondrogenic potential of the miPSC-MSC was deter-
mined in chondrogenic pellets, which formed a collagen type
II matrix (Figure 2(c)). Chondrogenic induction led to statis-
tically signiﬁcant increases in expression of chondrocyte-
associated gene collagen type II and SOX9 (Figure 2(c)).
4.3. miPSC-MSC Supress Activated Splenocytes In Vitro. The
immunomodulatory capacity of the miPSC-MSC was
assessed following coculture for 5 days with Con A-
stimulated mouse splenocytes prelabelled with the ﬂuores-
cence dye, carboxyﬂuorescein succinimidyl ester (CFSE),
which were then assessed using ﬂow cytometric analysis. In
the presence of miPSC-MSC, there was a statistically signiﬁ-
cant inhibition of proliferating splenocytes in all three donors
assessed, with coculture resulting in a signiﬁcant reduction in
proliferation between mitogen-activated splenocytes cul-
tured alone compared to those cocultured with miPSC-
MSC (Figure 3).
4.4. miPSC-MSC Inhibit Inﬂammation in an Acute
Periodontitis Sponge Model. To assess the immunomodula-
tory capacity of the miPSC-MSC in vivo, we employed a
sponge model of inﬂammation to elicit an acute and chronic
inﬂammatory response within the mice. Visual assessment of
the histology sections revealed less inﬂammatory cellular
inﬁltrate within the P. gingivalis containing implanted
sponges in mice treated with miPSC-MSC cells, compared
to sponges from control mice which received PBS sham treat-
ment alone (Figure 4(a)). Conﬁrmatory semiquantitative
analysis demonstrated a reduction in the inﬂammatory score
in mice, which received miPSC-MSC (Figure 4(b)). The
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Figure 1: Immunophenotype of the miPSC-MSC. Representative ﬂow cytometry analyses of primary mouse bone marrow MSC (mMSC),
noninduced miPSC (miPSC), miPSC induced to diﬀerentiate into MSC presorting (miPSC-MSC presort) and after sorting for CD105+,
and SSEA1 cells (miPSC-MSC after sort). MSC-related markers CD73, CD105, and Sca-1, pluripotency marker SSEA1, and
haematopoietic markers CD34 and CD45 were assessed (solid histogram) relative to their respective isotype controls (open histogram).
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systemic injection of miPSC-MSC via a tail vein injection of
the cells was not statistically signiﬁcant. Local injection of
the miPSC-MSC, via a subcutaneous injection of the cells,
resulted in a statistically signiﬁcant reduction in inﬂamma-
tory score (Figure 4(b)).
Gene expression levels of diﬀerent proinﬂammatory
cytokines were assessed in spleens harvested from mice,
by real-time PCR. CXCL1 transcripts were found to be
signiﬁcantly lower in mice, which received a tail vein















































































































































































Figure 2: Trilineage diﬀerentiation potential of the miPSC-MSC. (a) Representative image of the osteogenic diﬀerentiation potential of
miPSC-MSC-like cells visualised by Alizarin Red staining of mineralised deposits formed after 4 weeks of culture in osteogenic inductive
media. Real-time PCR analysis of the relative expression of genes associated with osteogenesis, bone sialoprotein-2 (BSP2), and
osteopontin (OPN). (b) Representative image of the adipogenic potential of miPSC-MSC visualised by Oil Red-O staining for lipid
formation after 4 weeks of culture in adipogenic induction medium. Real-time PCR analysis of the relative expression of genes associated
with adipogenesis CEBP-α and PPAR-γ2. (c) Representative image of the chondrogenic diﬀerentiation potential of miPSC-MSC visualised
by anticollagen type II antibody staining on the chondrocyte pellets formed after culture in chondrogenic media for 4 weeks. Real-time
PCR analysis of the relative expression of genes associated with chondrogenesis collagen type II (COL-2) and SOX9. The data represent
the mean expression values normalized to the housekeeping gene β-actin± SEM (∗p < 0 05 unpaired t-test).
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miPSC-MSC, in contrast to TNFα (Figure 5(a)). Concen-
trations of CXCL1 protein in blood serum trended
towards a lower level in mice injected with miPSC-MSC
through both tail vein and subcutaneous injections; how-
ever, the decreased levels were not statistically signiﬁcant
compared to the control animals (Figure 5(b)).
4.5. miPSC-MSC Supress Inﬂammation and Reduce Alveolar
Bone Loss in a P. gingivalis-Induced Chronic Periodontitis
Mouse Model. Histological analysis of periodontal struc-
tures in mice following oral inoculation with P. gingivalis
indicated less tissue destruction present in the jaws, which
received miPSC-MSC treatment compared to PBS alone
(Figure 6(a)). Micro-CT analysis conﬁrmed the histological
observations, revealing a statistically signiﬁcant smaller
area between the cementoenamel junction (CJE) and the
alveolar bone crest (ABC) bone volume in those mice, which
received miPSC-MSC when compared to PBS-treated mice
(Figure 6(b)). A reduced CEJ-ABC volume is indicative of
reduced bone erosion having occurred as a result of peri-
odontitis. Supportive data of inﬂammatory scores indicated
a nonsigniﬁcant trend towards reduced inﬂammation in
miPSC-MSC-treated animals (Figure 6(c)).
5. Discussion
Our study is a proof-of-concept assessment of whether the
conversion of iPSC into iPSC-MSC-like populations could
provide a potential alternative stem cell source to primary
MSC. We successfully generated miPSC-MSC-like cells,
which satisﬁed the International Society of Cellular Ther-
apy’s minimal criteria for deﬁning multipotent MSC [34],
based on their plastic adherent properties, expression of key
MSC-associated markers, and their ability to undergo triline-
age diﬀerentiation. However, further genetic proﬁling analy-
ses are required to determine the equivalence of iPSC-derived
MSC-like populations and primary MSC. Other reports have
described the diﬀerentiation of iPSC into MSC-like popula-
tions based on a range of methodologies [10, 11, 35–37]
and assessed their potential role in skeletal tissue repair and
regenerative medicine applications [38, 39]. One study
employed ﬂuorescence-activated cell sorting to purify
ESC-derived MSC, based on positive selection using MSC-
associated markers and negative selection for pluripotency-
associated markers [40]. The present study conﬁrmed that
positive immunoselection of iPSC-MSC post conversion,
based on CD105 expression, provided stable cultures of
CD105-sorted MSC-like populations uniformly expressing
MSC-associated markers, while lacking hematopoietic and
pluripotent markers. Given the limited life span of ex vivo
expanded primary MSC, the optimisation of protocols lead-
ing to stable iPSC-MSC preparations may eventually provide
an almost unlimited reservoir of MSC for diﬀerent regenera-
tive medicine applications. However, issue concerning iPSC-
MSC stability, safety, production quality, and cost need to be
addressed before this technology can be realized.
While regenerative capabilities of iPSC-MSC have
been a major focus in studies testing their eﬃcacy in dif-
ferent clinical indications, the immunomodulatory proper-
ties of iPSC-MSC have emerged as an exciting new area
of investigation into the therapeutic potential of iPSC-
MSC for a range of immune/inﬂammatory-based disease
models [13, 19, 22]. The present study conﬁrmed that
miPSC-MSC were capable of inhibiting the proliferation
of mitogen-stimulated splenocytes. Subsequent experi-
ments were performed to assess the eﬃcacy of iPSC-
MSC to inhibit inﬂammation and bone loss in two estab-
lished animal models of periodontitis. The ﬁrst approach
assessed the role of miPSC-MSC to inhibit the inﬂamma-
tion in mice implanted with sponges inﬁltrated with heat-
inactivated P. gingivalis bacteria. Histological assessment
revealed reduced trends in the level of inﬂammatory cel-
lular inﬁltrate within the sponges harvested from mice,
which received miPSC-MSC cells by intravenous injec-
tion, seven days after implantation of the P. gingivalis-
inﬁltrated sponges, compared to the sponges from control
mice which received PBS alone. However, local injection
of the miPSC-MSC via subcutaneous injection resulted
in a statistically signiﬁcant reduction in inﬂammatory
scores. Mice injected with miPSC-MSC-like cells also
showed a decrease in inﬂammation in the in vivo sponge
model, with signiﬁcant decreased gene expression of the
immunoregulatory cytokine CXCL1, but not other cyto-
kines such as TNFα, TGFβ, or IL-6 (data not shown).
The chemokine, CXCL1, binds to CXCR2 and is
expressed by macrophages, neutrophils, and epithelial
cells such as gingival ﬁbroblasts [41]. The CXCL1-
CXCR2 axis was found to play an important role in
mediating neutrophil recruitment in oral mucosa [42].
Moreover, CXCL1-CXCR2 interactions were shown to
























Figure 3: miPSC-MSC mediated suppression of activated
splenocytes. Relative proliferation index of the level of proliferation
of Con A-stimulated mouse splenocytes (splenocytes alone)
compared to splenocytes cocultured with miPSC-MSC as a 1 : 1
ratio. The proliferation level of the splenocytes cocultured with
miPSC-MSC was normalised to that of the splenocytes cultured
alone. Results show the mean± SEM data from 3 splenocyte
donors performed in triplicate (∗p < 0 05, unpaired t-test).
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stimulation of human periodontal ligament cells with the
inﬂammation promoter lipopolysaccharide (LPS) increased
periodontal ligament cell CXCL1 mRNA expression several
fold [44]. Another study, assessing candidate genes
associated with periodontitis, identiﬁed CXCL1 using an
integrative gene ranking method as one of the genes requir-


































Figure 4: In vivo assessment of the immunomodulatory properties of miPSC-MSC in a sponge model of periodontitis. (a) Representative
light microscopy images of H&E stained sections of the implanted sponges 14 days after the injection of PBS, or 5× 106 miPSC-MSC via
tail vein injection (IV) or subcutaneous injection (SC). (b) Semiquantitative scoring of the level of immune cell inﬁltrate present in
histological slides of the implanted sponges (∗p value <0.05 as determined by one-way ANOVA with multiple comparisons, n = 6).
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In a second animal study, we assessed the eﬃcacy of
miPSC-MSC intravenous injected into mice with induced
chronic periodontitis based on oral inoculation with P.
gingivalus. Micro-CT and histological analyses of the jaw
bones identiﬁed a statistically signiﬁcant smaller CEJ-ABC
bone volume in those mice which received miPSC-MSC
when compared to PBS-treated mice, indicative of reduced
bone erosion having occurred as a result of periodontitis.
These ﬁndings are consistent with the bone regenerative
eﬀect of iPSC-derived MSC delivered locally into rats with
surgically generated periodontal defects [9]. Collectively,
these ﬁndings indicate that the reduction of bone loss seen
by either systemic or local delivery of miPSC-MSC may be
attributed to the modulation of inﬂammatory responses. In
a gene therapy-based study, rat iPSC-MSC were genetically
engineered with TNFα-stimulated gene-6 (TSG-6), to assess
their potential to enhance the therapeutic eﬀects of iPSC-
MSC in experimental periodontitis, established by ligature
and infection with P. gingivalis around the maxillary ﬁrst
molar bilaterally [24]. The study found that systemic admin-
istration of TSG-6 overexpressing iPSC-MSC was capable of
decreasing inﬂammation in experimental periodontitis and
inhibiting alveolar bone resorption, over and above that
observed for control iPSC-MSC. TSG-6 has been reported
to have an anti-inﬂammatory eﬀect in several animal models,
including arthritis, myocardial infarction, and chemical
injury to cornea, and has been attributed to its inhibitory
eﬀects on neutrophil migration and plasmin activity [24].
In addition to lymphocyte, neutrophil, and macro-
phage populations, Tregs have been highly implicated in
periodontitis [46], where inhibition of Treg function
causes increased numbers of leukocytes within the peri-
odontal tissue and increased bone loss [47]. Furthermore,
an imbalance between Th17 and Treg cells has also been
suggested to lead to tissue destruction in periodontitis.
Reinforcing a role for Th17 and Treg cells in periodontitis
is the identiﬁcation that retinoic acid suppresses experi-
mental periodontitis through modulation of the Th17/Treg
imbalance that occurs in periodontitis [48]. Previous
reports have shown that iPSC-MSC cells are capable of
suppressing T-cell eﬀector populations, Th1/Th2/Th17
cells, and increase levels of Treg cells [13, 18, 22] suggest-
ing a potential role of these cells for the clinical prevention
of periodontitis using novel iPSC-MSC therapies [49].
Importantly, conversion of iPSC into MSC-like popula-





































































Figure 5: Assessment of cytokine levels in the sponge model of periodontitis. (a) Real-time PCR analysis of the expression of TNFα and
CXCL1 in the spleens of mice harvested from the sponge periodontitis model. The data represent the mean expression values for each
sample normalized to the housekeeping gene β-actin± SEM (∗p < 0 05 one-way ANOVA with multiple comparisons, n = 6). (b)
Multiplex analysis of the levels of TNFα and CXCL1 present in the blood serum of the mice from the sponge periodontitis
model (∗p < 0 05, ∗∗p < 0 01, one-way ANOVA with multiple comparisons, n = 6).
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formation in vivo. Comparative analyses of the bone-forming
capacity of nonhuman primate iPSC and iPSC-derived MSC
found no evidence of tumor formation by iPSC-MSC follow-
ing transplantation in vivo [12]. The ﬁndings showed that
autologous transplantation of iPSC seeded onto an osteocon-
ductive scaﬀold resulted in tumor formation and associated
inﬂammation in recipient animals, while iPSC-MSC formed
ectopic bone tissue with no associated tumor formation or
inﬂammation. In the present study, histological examination
of both periodontitis models found no evidence of tumor for-
mation or increased inﬂammatory responses. Although we
and others have not observed any teratogenic eﬀects of
iPSC-MSC in vivo, the safety concerns of genomic instability
of iPSC-derived MSC need to be carefully evaluated before
clinical translation. In summary, our results demonstrated
that miPSC-MSC can be derived from iPSC and that these
cells have the capacity to control the chronic inﬂammatory
response that leads to tissue destruction in periodontal
disease. Therefore, miPSC-MSC are a promising novel
source of stromal cells which could be used in the treat-
ment of periodontitis and other inﬂammatory systemic
diseases such as rheumatoid arthritis, following future
advancements in the production of safe and cost-eﬀective
iPSC-MSC preparations.
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